Mksap 16
Mksap 16
Mksap 16
2.
3.
4.
action of BAFF
acute vs chronic
inflamm or
noninflamm
oligoarthritis
advantage of
febuxostat over
allopurinol
adverse effects of
abatacept
adverse effects of
allopurinol
adverse effects of
uricase and
rasburicase
adverse events
related to
cyclophosphamide
ANCA-associated
vasculitides
13.
14.
15.
5.
6.
7.
8.
9.
10.
11.
12.
arthrocentesis
counts suggestive
of septic arthritis
corticosteroidsparing or
maintenance agent
in lupus,
vasculitis, and
polymyositis
azothioprine
cyclophosphamide
and pregnancy
16.
17.
18.
19.
20.
21.
22.
different
manifestations of
GCdepending on
blood vessel
involved
effect of
sulfasalazine in
male fertility
effective as initial
monotherapy for
patients with
rheumatoid
arthritis of any
duration or degree
of activity
methotrexate or leflunomide
enzyme tht
metabolizes
azathioprine
extra-articular
sequelae of RA
Felty syndrome
glomerulonephritis
associated with
small vessel
vasculitis
how does
methotrexate work
in rheuma
conditions?
how is diagnosis of
Wegener,ls
granulomatosis
established?
how is Takayasu
diagnosis
established?
demonstration of characteristic
narrowing of the aorta or its major
branch vessels
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
ustekinumab
hydroxychloroquine
pand pregnancy
indications for
colchicine
initial
monotherwpy for
RA with moderate
or high disease
activity
initial presentation
of Kawasaki
laboratory
abnormalities are
useful in
demonstrating the
presence of an
inflammatory
process
large vessel
vasculitis
leflunomide and
pregnancy
MOA
hydroxychloroquine
in rheumatologic
disease
MOA leflunomide
MOA mycophenolate
mofetil
38.
MOA of probenecid
39.
MOA rituximab
40.
MOA Tocilizumab
chimeric (mouse-human)
monoclonal antibody with specificity
for the IL-6 receptor; attenuates B
and T lymphocyte activation,
leukocyte migration, osteoclast
activation, and hepatic synthesis of
acute phase reactants
monoclonal antibody
with specificity for
B-cell-activating
factor (BAFF), also
referred to as Blymphocyte
stimulator (BLyS)
belimumab
keratoconjunctivitis sicca
most important
toxicity from
hydroxychloroquine
pegylated
recombinant
mammalian uricase
that has received
FDA approval for
treatment-failure
gout
pegloticase
35.
36.
37.
41.
42.
maintains the
gastric lining and
kidney blood flow
prostaglandin E2
medium size
vasulitis
PAN, Kawasaki
methotrexate
toxicities
44.
MOA abatacept
45.
43.
46.
47.
48.
49.
50.
primary
presenting features
of
cryoglobulinemic
vasculitis
side effects of
febuxostats
side effects of
leflunomide
hematopoietic abnormalities,
infection, and interstitial lung disease,
highly teratogenic
side effects of
probenecid
side effects of
rituxkmab
58.
59.
60.
51.
52.
53.
54.
55.
56.
57.
side effects of
tocilizumab
systemic vasculitis
in the spectrum of
hypereosinophilic
disorders that
most often occurs
in the setting of
antecedent asthma,
allergic rhinitis, or
sinusitis
Churg-Strauss syndrome
treatment
forpatients with
patients with
hepatitis Bassociated
polyarteritis
nodosa
treatment of GA
treatment of
hepatitis Cassociated
cryoglobulinemia
treatment of
Kawasaki disease?
61.
62.
type 1
cryoglobulins
type 2
cryoglobulins
usual setting
of PAN
when is urate
lowering
therapy
indicated?
when to use
abatacept